Global Cachexia Treatment Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Cachexia Treatment Market Research Report 2024
Cachexia is a wasting syndrome characterized by extreme weight loss, anorexia, asthenia and anaemia. This syndrome affects populations who were in the late stages of severe diseases like cancer, HIV or AIDS, kidney disease, COPD and congestive heart failure (CHF). Appetite stimulants, anti-inflammatory drugs, Corticosteroids, Enobosarm and Other Anabolics are most commonly used for cachexia treatment.
According to MRAResearch’s new survey, global Cachexia Treatment market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Cachexia Treatment market research.
Key companies engaged in the Cachexia Treatment industry include Alder Biopharmaceuticals Inc., GTx Inc., Helsinn Group, Merck & Co. Inc., Bristol-Myers Squibb Company, Helsinn Healthcare S.A., PsiOxus, Purdue Pharma L.P. and Eterna Zentaris Inc., etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Cachexia Treatment were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Cachexia Treatment market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Cachexia Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Alder Biopharmaceuticals Inc.
GTx Inc.
Helsinn Group
Merck & Co. Inc.
Bristol-Myers Squibb Company
Helsinn Healthcare S.A.
PsiOxus
Purdue Pharma L.P.
Eterna Zentaris Inc.
Aphios Corporation
Neurim
Novartis AG
SkyePharma
Segment by Type
Weight Loss Stabilizers
Appetite Stimulants
Progestogens
Corticosteroids
Combination therapies
Others
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Cachexia Treatment report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to MRAResearch’s new survey, global Cachexia Treatment market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Cachexia Treatment market research.
Key companies engaged in the Cachexia Treatment industry include Alder Biopharmaceuticals Inc., GTx Inc., Helsinn Group, Merck & Co. Inc., Bristol-Myers Squibb Company, Helsinn Healthcare S.A., PsiOxus, Purdue Pharma L.P. and Eterna Zentaris Inc., etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Cachexia Treatment were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Cachexia Treatment market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Cachexia Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Alder Biopharmaceuticals Inc.
GTx Inc.
Helsinn Group
Merck & Co. Inc.
Bristol-Myers Squibb Company
Helsinn Healthcare S.A.
PsiOxus
Purdue Pharma L.P.
Eterna Zentaris Inc.
Aphios Corporation
Neurim
Novartis AG
SkyePharma
Segment by Type
Weight Loss Stabilizers
Appetite Stimulants
Progestogens
Corticosteroids
Combination therapies
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Cachexia Treatment report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source